Disease Burden and Unmet Need in Eosinophilic Esophagitis.

Details

Ressource 1Download: 35417421.pdf (1128.58 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_CAD58AB5D2A0
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Disease Burden and Unmet Need in Eosinophilic Esophagitis.
Journal
The American journal of gastroenterology
Author(s)
Bredenoord A.J., Patel K., Schoepfer A.M., Dellon E.S., Chehade M., Aceves S.S., Spergel J.M., Shumel B., Deniz Y., Rowe P.J., Jacob-Nara J.A.
ISSN
1572-0241 (Electronic)
ISSN-L
0002-9270
Publication state
Published
Issued date
01/08/2022
Peer-reviewed
Oui
Volume
117
Number
8
Pages
1231-1241
Language
english
Notes
Publication types: Journal Article ; Review ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Eosinophilic esophagitis (EoE) is a chronic, progressive, type 2 inflammatory disease of increasing prevalence, characterized by symptoms of dysphagia and reduced quality of life. A dysregulated type 2 immune response to food and aeroallergen leads to barrier dysfunction, chronic esophageal inflammation, remodeling, and fibrosis. Patients with EoE have impaired quality of life because of dysphagia and other symptoms. They may also suffer social and psychological implications of food-related illness and expensive out-of-pocket costs associated with treatment. Disease burden in EoE is often compounded by the presence of comorbid type 2 inflammatory diseases. Current conventional treatments include elimination diet, proton pump inhibitors, and swallowed topical corticosteroids, as well as esophageal dilation in patients who have developed strictures. These treatments demonstrate variable response rates and may not always provide long-term disease control. There is an unmet need for long-term histologic, endoscopic, and symptomatic disease control; for targeted therapies that can normalize the immune response to triggers, reduce chronic inflammation, and limit or prevent remodeling and fibrosis; and for earlier diagnosis, defined treatment outcomes, and a greater understanding of patient perspectives on treatment. In addition, healthcare professionals need a better understanding of the patient perspective on disease burden, the disconnect between symptoms and disease activity, and the progressive nature of EoE and the need for continuous monitoring and maintenance treatment. In this review, we explore the progression of disease over the patient's lifespan, highlight the patient perspective on disease, and discuss the unmet need for effective long-term treatments.
Keywords
Cost of Illness, Deglutition Disorders/complications, Eosinophilic Esophagitis/diagnosis, Eosinophilic Esophagitis/epidemiology, Eosinophilic Esophagitis/therapy, Fibrosis, Humans, Inflammation/complications, Proton Pump Inhibitors/therapeutic use, Quality of Life
Pubmed
Web of science
Open Access
Yes
Create date
19/04/2022 9:33
Last modification date
27/08/2024 7:31
Usage data